Objective To update the evidence on efficacy and safety of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …

Objective To update the evidence of non-biological treatments for axial spondyloarthritis
(axSpA), as a basis for the 2022 Assessment of SpondyloArthritis international Society …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …

Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and
polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to …

Objective: Few real-world studies have shown clear association between interleukin (IL)-17
inhibitors and inflammatory bowel disease (IBD) onset. This study investigated the reporting …

Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory
diseases that can affect both axial and peripheral joints, tendons and entheses. Among the …

Background Overweight and/or obese patients with inflammatory arthritis (IA) have higher
disease activity and lower chances of achieving and/or maintaining the treatment targets …

Over the recent years the wider availability and application of state-of-the-art immunological
technologies greatly advanced the insight into the mechanisms that play an important role in …

Background There is a growing interest in understanding the early disease stages of axial
and peripheral SpA (axSpA and pSpA). In order to facilitate this, standardized definitions are …